Back to Search
Start Over
Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events.
- Source :
-
The Journal of dermatology [J Dermatol] 2020 Feb; Vol. 47 (2), pp. e43-e44. Date of Electronic Publication: 2019 Nov 24. - Publication Year :
- 2020
- Subjects :
- Biomarkers blood
Humans
Imidazoles adverse effects
Lung diagnostic imaging
Lung Neoplasms diagnosis
Lung Neoplasms secondary
Male
Melanoma diagnosis
Melanoma genetics
Melanoma secondary
Mutation
Oximes adverse effects
Proto-Oncogene Proteins B-raf antagonists & inhibitors
Proto-Oncogene Proteins B-raf genetics
Pyridones adverse effects
Pyrimidinones adverse effects
Skin Neoplasms genetics
Skin Neoplasms therapy
Young Adult
Antineoplastic Combined Chemotherapy Protocols adverse effects
Fibrinolysis drug effects
Lung Neoplasms drug therapy
Melanoma therapy
Procalcitonin blood
Skin Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1346-8138
- Volume :
- 47
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- The Journal of dermatology
- Publication Type :
- Report
- Accession number :
- 31762081
- Full Text :
- https://doi.org/10.1111/1346-8138.15163